Rite Aid Corporation Earnings: Can the Good Times Last?

The drugstore chain has been on a roll lately, but can Rite Aid keep climbing higher?

Apr 8, 2014 at 11:13AM

On Thursday, Rite Aid (NYSE:RAD) will release its quarterly report, and investors have continued to enjoy the fruits of the drugstore chain's recovery over the past year. Yet despite Rite Aid's bounce, the big question is whether it can still hold off strong competition from Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS) at the same time it takes care of its own financial situation and improves its balance sheet further.

Rite Aid has long struggled behind CVS and Walgreen in the drugstore niche, hampered by high debt and failing to see the growth its peers enjoyed. Yet even after many investors left Rite Aid for dead, the stock delivered impressive returns last year, and the chain's growth has surprised even many of the company's staunchest advocates. Now, shareholders want to see if Rite Aid can repeat last year's share-price gains in 2014. Let's take an early look at what's been happening with Rite Aid over the past quarter and what we're likely to see in its report.


Stats on Rite Aid

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$6.54 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Can Rite Aid earnings keep growing?
In recent months, analysts have had mixed views on Rite Aid earnings, cutting a penny per share from their February-quarter estimates, but raising full-year fiscal 2015 projections by the same penny. The stock has kept climbing, though, posting a 20% gain since early January.

Rite Aid has delivered fairly solid growth numbers on a monthly basis all quarter, with a 2.9% rise in same-store sales in December, followed by 1.8% comp gains in January and 1.5% in February. Yet by March, comp growth had fallen to just 0.7%, and front-end store comps have been consistently terrible even as the pharmacy side of Rite Aid's business remains strong. Moreover, putting Rite Aid's recovery in context, the drugstore still makes less in revenue than it did in 2010, while both Walgreen and CVS have seen sales gains.

One huge long-term benefit to Rite Aid has come from the rise of generic drugs. Because of the recent patent cliff, many popular drugs now face generic competition, and that has reduced the price Rite Aid and its peers have to pay. That in turn boosts Rite Aid's gross margins, although it opens the door to tougher price competition with Walgreen and CVS, because generics give them more flexibility to use pricing power without sacrificing too much margin. You can see the net impact fall through to Rite Aid's operating margins, which have risen at a far greater pace than those of its two main rivals over the past 12 months.

But Rite Aid is looking for new ways to grow as well. Last week, Rite Aid announced it had bought patient-support and health-care analytics company Health Dialog Services, with the intention of using it to grow its new Rite Aid Health Alliance between its stores and health-care providers. With the service currently available in three cities, including Los Angeles, Buffalo, N.Y., and Greensboro, N.C., Rite Aid hopes to make it easier for customers to coordinate with their physicians -- and at the same time build customer loyalty.

One interesting issue Rite Aid will have to address is whether to keep selling cigarettes. CVS chose earlier this year to stop cigarette sales, and more than two dozen attorneys general in states across the nation have called on Rite Aid, Walgreen, and other pharmacies to follow suit, citing "a contradiction in having these dangerous and devastating tobacco products on the shelves of a retail chain that services health care needs." Rite Aid has to decide whether losing profits from tobacco will offset any potential gain from making the move, and with CVS having been the first mover, Rite Aid won't be able to get nearly as much marketing value from such a move.

In the Rite Aid earnings report, watch to see how the company positions itself to address its weak front-of-store sales results. Prescription growth has been great, but Rite Aid needs to get its whole store working better if it wants to sustain the big gains in its share price.

Three stocks poised to be multibaggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multibagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report you can download instantly by clicking here now.

Click here to add Rite Aid to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers